4.7 Article

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Damian Wild et al.

JOURNAL OF NUCLEAR MEDICINE (2014)

Article Radiology, Nuclear Medicine & Medical Imaging

Measured Human Dosimetry of 68Ga-DOTATATE

Ronald C. Walker et al.

JOURNAL OF NUCLEAR MEDICINE (2013)

Article Radiology, Nuclear Medicine & Medical Imaging

Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors

Mattias Sandstrom et al.

JOURNAL OF NUCLEAR MEDICINE (2013)

Article Radiology, Nuclear Medicine & Medical Imaging

Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications

Melpomeni Fani et al.

JOURNAL OF NUCLEAR MEDICINE (2012)

Article Endocrinology & Metabolism

The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

Ben Lawrence et al.

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro

Renzo Cescato et al.

JOURNAL OF NUCLEAR MEDICINE (2011)

Article Radiology, Nuclear Medicine & Medical Imaging

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Flavio Forrer et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)

Article Multidisciplinary Sciences

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

Mihaela Ginj et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)